Literature DB >> 34718339

Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials.

Ashish Sharma1, Nilesh Kumar2,3, Nikulaa Parachuri2,4, Dhatri Karanam2, Baruch D Kuppermann5, Francesco Bandello6, Carl D Regillo7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34718339      PMCID： PMC8956679          DOI： 10.1038/s41433-021-01831-4

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be Explored.

Authors:  Ashish Sharma; Nikulaa Parachuri; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein; Carl D Regillo
Journal:  Ophthalmol Retina       Date:  2019-07-10

2.  Faricimab: Two in the Bush Is Proving Better than One in the Hand?

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal:  Ocul Immunol Inflamm       Date:  2021-07-09       Impact factor: 3.070

3.  Faricimab: expanding horizon beyond VEGF.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2019-11-06       Impact factor: 3.775

4.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

5.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Authors:  Jeffrey S Heier; Jean-François Korobelnik; David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Edoardo Midena; David S Boyer; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Frank G Holz
Journal:  Ophthalmology       Date:  2016-09-17       Impact factor: 12.079
  5 in total
  1 in total

1.  Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Authors:  Sophia Stock; Mohamed-Reda Benmebarek; Anna-Kristina Kluever; Diana Darowski; Christian Jost; Kay-Gunnar Stubenrauch; Joerg Benz; Anne Freimoser-Grundschober; Ekkehard Moessner; Pablo Umana; Marion Subklewe; Stefan Endres; Christian Klein; Sebastian Kobold
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.